ARS Pharmaceuticals, Inc. Common Stock
SPRYARS Pharmaceuticals, Inc. (SPRY) is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of acute care medical conditions. The company primarily specializes in rescue treatments for severe allergies, anaphylaxis, and other urgent medical needs, aiming to improve patient outcomes through its proprietary drug delivery systems.
Company News
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7 million, with neffy (epinephrine nasal spray) generating $17.5 million in U.S. net product revenue. The company expanded its sales force to 148 representatives, secured approval from Health Canada, and achieved European Commission marketing authorization for EURneffy 1 mg. CVS Caremark f...
ARS Pharmaceuticals (Nasdaq: SPRY) announced a conference call scheduled for May 15, 2026, to discuss its first quarter 2026 financial results and business highlights. The company continues commercializing neffy®, an epinephrine nasal spray for emergency treatment of allergic reactions and anaphylaxis across multiple markets including the U.S., ...
ARS Pharmaceuticals reported $32.5 million in revenue for Q3 2025, primarily from neffy epinephrine nasal spray sales. The company continues to expand market presence through direct-to-consumer campaigns and has strong cash reserves of $288.2 million.
ARS Pharmaceuticals reported strong Q2 2025 revenue of $15.7 million, driven by its needle-free epinephrine nasal spray neffy. Prescription volumes grew 180%, and commercial coverage reached 93%, though high operating costs led to a net loss of $44.9 million.
ARS Pharmaceuticals has filed for approval of its epinephrine nasal spray 'neffy' in Canada and the United Kingdom, where it will be marketed as 'EURneffy', on behalf of its licensing partner ALK-Abelló A/S. The filing is part of the company's efforts to expand the global availability of this life-saving treatment for severe allergic reactions.
